Background-Intra-aortic balloon pumps (IABP) frequently are used to provide hemodynamic support during high risk percutaneous coronary intervention (PCI), but clinical evidence to support their use is mixed. We examined hospital variation in IABP use among high risk PCI patients, and determined the association of IABP use on mortality in this population. 
WHAT IS KNOWN
• Intra-aortic balloon pumps can be used to provide hemodynamic support to patients undergoing highrisk PCI.
• Studies evaluating the effectiveness of IABPs for this purpose have shown conflicting results.
WHAT THE STUDY ADDS
• The proportion of high-risk PCI patients who have an IABP placed varies widely across hospitals (median 9.3%, interquartile range 6.5-14.2%; range 0 -40%).
• The outcomes of patients treated at hospitals that used IABP less frequently were comparable with those of patients treated at hospitals that used IABP more frequently.
• These findings should prompt hospitals performing high-risk PCI to closely examine their practice regarding the use of IABP given the absence of data clearly identifying a benefit from IABP use.
Methods

Data Source
The CathPCI Registry has been described previously. 15 In brief, the CathPCI Registry is a national, voluntary cardiac catheterization laboratory registry that catalogs the clinical data and outcomes of both cardiac catheterization and PCI at more than 600 hospitals across the United States. The registry includes a standardized set of data elements and definitions, systematic data entry and transmission procedures, and rigorous data quality assurance standards. The complete definitions of all variables were prospectively defined by a committee of the American College of Cardiology (ACC) and are available at the ACC Web site (http://www.acc.org/ncdr/ cathlab.htm). Data are collected retrospectively or concurrently and represent consecutive patients treated at each institution and submitted to the CathPCI Registry. All data undergoes extensive quality checks, and a random sample of CathPCI sites undergo external auditing to further ensure data quality.
Patient Population
To examine patterns of IABP use and to determine its association with outcomes, we identified a cohort of admissions for patients undergoing high risk PCI at a participating hospital between January 1, 2005 and December 31, 2007 (nϭ192 716). PCI was considered to be high risk if at least 1 of the following features was present: unprotected left main artery as the target vessel, cardiogenic shock, severely depressed left ventricular function (Ͻ30%), or ST segment elevation myocardial infarction. 14 For patients with more than 1 PCI during a single hospital admission, we excluded data from the additional PCI (nϭ9230). In addition, we excluded PCIs in which it could not be determined whether an IABP was inserted (nϭ5), PCIs performed on patients with severe aortic insufficiency (nϭ3360), and PCIs performed at hospitals that averaged fewer than 10 high risk PCIs per year (nϭ1170). A total of 181 599 high risk patients who underwent PCI at 681 hospitals were available for analysis.
Outcomes
The primary outcome of the study was in-hospital mortality. Secondary outcomes of interest included vascular complications: bleeding (drop in hemoglobin Ͼ3 g/dL or hematoma Ͼ10 cm), access artery occlusion (total obstruction of the vessel requiring surgical repair), pseudoaneurysm, dissection, and embolism.
Data Analysis
Using the cohort defined above, we examined the proportion of high risk PCI patients who received an IABP across NCDR hospitals. We compared demographics, cardiac status, comorbid conditions, and cardiac anatomy between patients who did and did not have an IABP inserted during high risk PCI. A 2 test was used for categorical variables, and an F-test from ANOVA was used for continuous variables. In order to identify the factors most strongly associated with IABP placement, we developed a logistic regression model with the receipt of an IABP as the dependent variable. Candidate variables were identified on the basis of clinical sensibility and review of the literature, and selected for inclusion in the final model using stepwise selection (entry PՅ0.15, retention PՅ0.05). Multicollinearity was evaluated through examination of Pearson Correlation Coefficients. Variables included in the final model included demographics (age, gender, race, and payor), cardiac status (admitting symptoms, cardiogenic shock, presence of heart failure, New York Heart Association class, left ventricular ejection fraction, and results of noninvasive testing), past medical history (prior myocardial infarction, history of valve surgery, diabetes, renal dysfunction, renal dialysis, peripheral vascular disease, hypertension, tobacco use, chronic lung disease, dyslipidemia, family history of coronary artery disease, and prior PCI or coronary artery bypass grafting), and procedural characteristics (PCI status, door to balloon time). To assess the extent to which variation in the use of IABP was explained by clustering at the site level (ie, by differences across hospitals), we developed a hierarchical logistic regression model using the variables identified previously and calculated a hospital-specific median odds ratio (OR). 16, 17 The median OR represents that odds that identical patients We then assessed the association of IABP use with outcomes. To accomplish this, we categorized hospitals by their proportional use of IABP in high risk PCI and grouped them into corresponding quartiles. We compared sociodemographics, past medical history, cardiac status, and past medical history of patients treated at hospitals with high and low proportional IABP use. We also compared hospitals' characteristics, including profit type, number of beds, teaching status, census region, and annual volume of high risk PCI across hospital quartiles. We performed multivariable hierarchical logistic regression with in-hospital mortality as the dependent variable. The model adjusted for patient characteristics and hospitallevel variables, significantly associated IABP use identified in the previous model. In order to examine the relative contribution of each class of variables to the model, we repeated the hierarchical logistic regression models in a sequential fashion by incrementally introducing demographics, cardiac status, past medical history, and hospital characteristics into the models.
We further assessed the association of IABP with outcomes within subgroups of high risk PCI. For each subgroup, we performed multivariable hierarchical logistic regression analysis to determine the independent association of IABP use and mortality. Additional sensitivity analyses were performed excluding patients whose PCI was characterized as salvage, and again excluding patients with peripheral vascular disease in whom IABP insertion may not have been possible. Finally, adjusted analyses were repeated to assess the independent association of differences in IABP with vascular complications, including hematoma, access site occlusion, peripheral embolization, dissection, pseudoaneurysm, and arteriovenous fistula. All analyses were performed using SAS 9.1 (Cary, NC). The Yale Human Investigation Committee approved the analysis and determined that informed consent was not applicable to the data collected by the registry. Patients who received an IABP were a higher risk population than patients without an IABP (Table 1) . Notably, IABP patients were older, more likely to have had renal insufficiency, present with non-STEMI, New York Heart Association class IV heart failure, or cardiogenic shock. There were statistically significant but clinically modest differences between the treating hospital characteristics of patients who did and did not receive an IABP. In multivariable analysis, the factors that were strongly associated with IABP use included cardiogenic shock, left ventricular ejection fraction, non-STEMI, heart failure on admission, and admission status. The model had a high c-statistic (0.82), but the high Hosmer-Lemeshow 2 of 181 (PϽ0.001) suggests poor model calibration. In the hierarchical model, the median OR for the hospital effect was 1.93, suggesting a 93% greater odds of patients with identical covariates receiving an IABP at 1 randomly selected hospital compared with another ( Table  2) . As expected, the magnitude of the median OR is lower than certain clinical variables, such as cardiogenic shock and LVEF. However, it does suggest that the hospital effect is exerting a significant influence on the decision of whether or not to use an IABP.
Results
Among
Hospitals were grouped by proportional IABP use into quartiles as follows: Q1 (0.0 to 6.5%), Q2 (6.6 to 9.2%), Q3 ACS indicates acute coronary syndrome; CAD, coronary artery disease; CABG, coronary artery bypass grafting; CHF, congestive heart failure; HMO, Health Maintenance Organization; IABP, intra-aortic balloon pump; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.
(9.3 to 14.1%), and Q4 (14.2 to 40.0%). The characteristics of hospitals with a low proportion of IABP use were comparable with those of hospitals with a high proportion of IABP use (Table 3) . However, patient characteristics varied significantly across the hospital quartiles such that patients treated at hospitals in Q4 were older and had lower LVEF, and a higher proportion had renal dysfunction, prior congestive heart failure, diabetes, prior coronary artery bypass grafting, and cardiogenic shock compared with patients treated at hospitals in Q1-Q3 (Table 3) . Of note, a lower proportion of patients treated at Q4 hospitals presented with STEMI but a higher proportion underwent salvage PCI compared with Q1-Q3 hospitals. Unadjusted mortality in the study cohort was 4.9% and increased in a near linear fashion across hospital quartiles (Q1, 4.2; Q2, 4.8%; Q3, 5.1%; Q4, 5.6%; 
PϽ0.001).
The multivariable mortality had high c-statistic (0.89), but similar issues with model calibration (HosmerLemeshow 2 86.9, PϽ0.001). After adjustment for differences in patient and hospital characteristics, in-hospital mortality did not vary across hospital quartiles (Table 4) . Sequential introduction of variables into the model suggested that differences in mortality were to a large degree explained by differences in the cardiac status of patients undergoing high risk PCI. Differences in demographics, past medical history, and hospital characteristics had relatively little impact on the point estimates and associated confidence intervals. Similar findings were observed in subgroup analyses such that there was no subgroup in which a higher proportional use of IABP was associated with improved outcomes. Furthermore, findings were unchanged in the sensitivity analyses, excluding patients undergoing salvage PCI and peripheral vascular disease.
Unadjusted complication rates differed significantly across hospital quartiles (Table 5) 
Discussion
In this cohort of high risk PCI patients, IABP use varied significantly across hospitals. However, the observed variation in IABP use was not associated with differences in either in-hospital mortality or complication rates across hospitals. The outcomes of patients treated at hospitals using IABP more selectively were comparable with those of patients treated at hospitals that used IABP more frequently. Our findings provide no evidence to support the greater use of IABP at some hospitals and indicate a pressing need to further define the settings where this intervention provides a net benefit.
Data from the Benchmark Registry suggest that a fifth of all IABP insertions occur in the setting of PCI, and that half of those are performed to provide support and stabilization to patients who are not in cardiogenic shock. 18 In the present analysis, IABPs were used in slightly less than 10% of high risk PCI, and hospital use varied such that there was a nearly 2-fold difference in IABP use between hospital quartiles that used IABP more and less frequently. Similar variation has been demonstrated in rates of IABP use during coronary artery bypass grafting. 19 These findings highlight the fact that much of IABP use is discretionary. The decision to insert an IABP is likely influenced by physician training, clinical experience, and local practice patterns rather than high quality evidence from clinical studies. To date, however, these favorable properties of IABP have not been convincingly linked to improvements in patient outcome.
The evidence that supports IABP for high risk PCI comes from case series 20 -22 and retrospective analyses. 2,4 -6,13 Although these studies demonstrated feasibility and suggested efficacy of routine IABP use, their findings have not been supported by data from randomized trials. In randomized trials that enrolled patients with acute myocardial infarction ACS indicates acute coronary syndrome; CAD, coronary artery disease; CABG, coronary artery bypass grafting; CHF, congestive heart failure; HMO, Health Maintenance Organization; IABP, intra-aortic balloon pump; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SD, standard deviation.
(AMI) undergoing primary PCI, routine IABP use was not associated with differences in procedural success or clinical outcomes. 8, 9, 11, 12 Collectively, these studies do not support the routine use of IABP for patients at high risk of adverse outcomes, but leaves open the question of how aggressive we should be in using this technology.
Several factors have likely contributed to the gap between practice and evidence. First, recruiting patients into randomized trials of IABP has proven difficult. For example, 2 trials examining the effect of IABP patients with cardiogenic shock failed to meet target enrollment. 23 Second, advances in technology, particularly the routine use of coronary stents, have improved procedural success and significantly reduced risks associated with PCI. 24 As procedural risks have declined, identifying patients who are at sufficiently high risk of hemodynamic compromise that an IABP would be useful becomes increasingly difficult. Third, in the absence of definitive evidence, physicians and institutions have developed individual thresholds for IABP use. Once practitioners have established a routine use of a new technology, the perceived need to formally evaluate its efficacy may diminish.
Our data cannot be used to define the precise threshold at which an IABP would be beneficial. There are patients, notably those who present with or develop cardiogenic shock refractory to volume expansion, who likely benefit from IABP use, and studies suggest that IABPs have been persistently underused in this situation. 1, 25 Instead, the results of this analysis highlight the variations in IABP use that exist across hospitals, and should prompt interventional cardiologists and PCI-capable hospitals to critically examine their practice patterns and, perhaps, consider adopting a more selective approach to IABP use in high risk PCI. There are several important limitations to this analysis. First, this is a retrospective analysis of registry data. As such, we cannot exclude the possibility that unmeasured factors may confound our results. For example, although the NCDR contains more than 120 fields, including the presence of cardiogenic shock, it does not directly capture potentially important variables such as baseline heart rate or blood pressure. Second, we did not perform a formal power calculation to determine whether we had enough power to detect significant differences in mortality across hospitals performing high risk PCI. Nevertheless, with a cohort of more than 180 000 high risk PCI and an overall mortality rate of 4.9%, we believe we could detect clinically meaningful differences across hospitals. Third, the observed variation in hospital use of IABP may not be due to difference in practice patterns, but may instead be a marker for differences between hospitals, such as the skill of the interventional cardiologist, the quality of both intraand postprocedural care, or case mix. If so, higher rates of IABP use may mask significant differences in patient outcomes that would otherwise be measurable. Finally, our analysis did not address the timing of IABP use in relation to the performance of PCI, and this may be an important mediator of the benefits of discretionary IABP use.
In conclusion, among hospitals that participate in the NCDR, there was significant variation in the rate of IABP during and after high risk PCI. However, we found no evidence that the outcomes of patients treated at hospitals that used IABP more frequently were better than those of patients treated at hospitals that used IABP less frequently. These findings should prompt a reevaluation of the threshold for IABP in this population.
